These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29305415)

  • 1. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
    Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
    Zhang P; Zhang M
    Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
    Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
    Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
    Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
    Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
    Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis.
    Tonozuka Y; Tanaka H; Nomura K; Sakaguchi K; Soeda J; Kakimoto Y
    Cancer Chemother Pharmacol; 2024 Feb; 93(2):137-149. PubMed ID: 37921901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
    Li YY; Wang YF; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.
    Jiang T; Wang F; Hu L; Cheng X; Zheng Y; Liu T; Jia Y
    Oncotarget; 2017 Sep; 8(44):77586-77594. PubMed ID: 29100410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
    Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
    Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.
    Fernandez-Pol S; Ma L; Joshi RP; Arber DA
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):416-422. PubMed ID: 29629950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
    Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
    Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Liu QX; Zhu Y; Yi HM; Shen YG; Wang L; Cheng S; Xu PP; Xu HM; Zhou LT; Huang YH; Huang CX; Fu D; Ji MM; Wang CF; Zhao WL
    Int J Biol Sci; 2024; 20(10):3972-3985. PubMed ID: 39113693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
    Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
    Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
    Zhang H; Dong L; Chen Q; Kong L; Meng B; Wang H; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X
    Leuk Res; 2017 May; 56():29-35. PubMed ID: 28171799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.
    Laginestra MA; Cascione L; Motta G; Fuligni F; Agostinelli C; Rossi M; Sapienza MR; Righi S; Broccoli A; Indio V; Melle F; Tabanelli V; Calleri A; Novero D; Facchetti F; Inghirami G; Sabattini E; Bertoni F; Pileri SA
    Mod Pathol; 2020 Feb; 33(2):179-187. PubMed ID: 31028364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.